|
| 36550348 | Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. | Cardiovasc Drugs Ther | 2024 |
| 36331326 | Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. | Eur Heart J | 2023 |
| 38016401 | Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. | Atherosclerosis | 2023 |
| 38057066 | Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials. | J Am Coll Cardiol | 2023 |
| 37730294 | Ethics in Cardiovascular Care: A Call to Action. | J Am Coll Cardiol | 2023 |
| 37252442 | Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. | Am J Prev Cardiol | 2023 |
| 37282500 | Plain language summary of results from ORION-10 and ORION-11: two studies to learn how well inclisiran works in people with high cholesterol. | Future Cardiol | 2023 |
| 36620965 | Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. | Lancet Diabetes Endocrinol | 2023 |
| 36603959 | Decreasing Door-to-Diagnosis Time in Cardiac Amyloidosis: A Simple "One-Stop Shop" Approach. | Mayo Clin Proc | 2023 |
| 35303377 | Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. | Am J Hematol | 2022 |
| 35787849 | Solving the Puzzle of Coronary Artery Disease in the Elderly. | Mayo Clin Proc | 2022 |
| 36331315 | Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. | Eur Heart J | 2022 |
| 36344142 | Late Treatment for COVID-19 With Convalescent Plasma. | Chest | 2022 |
| 35013614 | Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19. | Nat Med | 2022 |
| 35155458 | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma. | Front Med (Lausanne) | 2022 |
| 32243492 | Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. | Cardiovasc Res | 2021 |
| 33794646 | Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. | Circ Genom Precis Med | 2021 |
| 33851186 | Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives? | medRxiv | 2021 |
| 33851175 | Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma. | medRxiv | 2021 |
| 33663735 | Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. | J Am Coll Cardiol | 2021 |
| 33501470 | The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma. | medRxiv | 2021 |
| 33523609 | Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. | N Engl J Med | 2021 |
| 34874424 | Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk. | JAMA | 2021 |
| 34928960 | Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. | PLoS Med | 2021 |
| 34736608 | Research Involving Participants With Impaired Consent Capacity: An Examination of Methods to Determine Capacity to Consent. | Mayo Clin Proc | 2021 |
| 34353476 | In Reply-How Safe Is COVID-19 Convalescent Plasma? | Mayo Clin Proc | 2021 |
| 34036587 | Use of convalescent plasma in COVID-19 patients with immunosuppression. | Transfusion | 2021 |
| 33958057 | The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. | Mayo Clin Proc | 2021 |
| 33413815 | Ethical Challenges in COVID-19 Biospecimen Research: Perspectives From Institutional Review Board Members and Bioethicists. | Mayo Clin Proc | 2021 |
| 31630870 | Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. | Mayo Clin Proc | 2020 |
| 33153626 | Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors. | Mayo Clin Proc | 2020 |
| 32861333 | Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. | Mayo Clin Proc | 2020 |
| 32817978 | Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. | medRxiv | 2020 |
| 32866446 | Characteristics and Long-Term Outcomes of Patients With Prior Coronary Artery Bypass Grafting Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. | Am J Cardiol | 2020 |
| 32187462 | Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. | N Engl J Med | 2020 |
| 32525844 | Early safety indicators of COVID-19 convalescent plasma in 5000 patients. | J Clin Invest | 2020 |
| 32376104 | Public Health Crises and the Human Subjects of Biomedical Research: A Focus on COVID-19. | Mayo Clin Proc | 2020 |
| 32200978 | Homeless With a Heart Attack in America-A Double Whammy. | Mayo Clin Proc | 2020 |
| 32511566 | Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. | medRxiv | 2020 |
| 32370846 | Algorithms and Bioethics. | Mayo Clin Proc | 2020 |
| 30611452 | A New Fix for the Bishop's Hat, Let's Give It Time to Wear Before We Pass Judgment. | Mayo Clin Proc | 2019 |
| 31553410 | Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. | JAMA Cardiol | 2019 |
| 31260901 | Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. | Am Heart J | 2019 |
| 31486375 | Mitigating Risk Patients With Dyslipidemia: A Statin a Day Does Not Always Keep the Doctor Away in Those With Elevated Triglycerides. | Mayo Clin Proc | 2019 |
| 30487231 | Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. | Diabetes Care | 2019 |
| 29735484 | Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. | Circulation | 2018 |
| 30193668 | Social Media Posts and Search Engine Queries as the Canary in the Coal Mine for Public Health Surveillance. | Mayo Clin Proc | 2018 |
| 30046837 | Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. | JAMA Cardiol | 2018 |
| 30227963 | Comparison of Mortality Risk Prediction Among Patients â¿¥70 Versus <70 Years of Age in a Cardiac Intensive Care Unit. | Am J Cardiol | 2018 |
| 29525785 | Predictive Value of the Sequential Organ Failure Assessment Score for Mortality in a Contemporary Cardiac Intensive Care Unit Population. | J Am Heart Assoc | 2018 |